Avandia May be More Dangerous Than Previously Thought

LegalView Updates Avandia Information Portal with News That Avandia May be More Dangerous Than Similar Drugs

LegalView recently relaunched is Avandia information portal with updated news that the type 2 diabetes drug has more safety risks than drugs of a similar nature. A study from U.S. researchers was published evaluating the dangers of the diabetes drugs and found Avandia as riskier for patients than Actos.

Denver, CO, December 02, 2008 -- LegalView.com, the number one resource for everything and anything legal on the Web, recently announced an update to its Avandia information portal with news that the type 2 diabetes drug poses more safety risks to patients than similar drugs including Actos. According to a Reuters article published in November, the Avandia study as well as analysis has been conducted of the drugs and has found that of both Avandia and Actos, Avandia poses greater risks, especially among older-aged diabetic patients and that the risks include an increased chance of developing heart disease.

Individuals who consume Avandia and who are concerned about the Avandia side effects, which may potentially include early on-set osteoporosis as well as heart failure, according to the New England Journal of Medicine, may need to discuss discontinuing use of the drug with a medical professional. Additionally, contacting an experienced pharmaceutical and Avandia attorney who may be able to provide a free legal consultation as to the development of a potential Avandia class action lawsuit.

 Avandia was first introduced from GlaxoSmithKline in May 1999 and was prescribed to nearly 3 million type 2 diabetes sufferers. In 2007 a U.S. Food and Drug Administration (FDA) health advisory alert was issued regarding the discovery of the alleged link that Avandia patients may be at a greater risk for developing heart disease and heart failure, while also being more susceptible to broken bones and fractures due to a potential osteoporosis risk. Patients consuming the drug should speak with their physician as well as consider the development of litigation for the potential of earning monetary compensation.

LegalView has also made available information portals on several other topics ranging from information on traumatic brain injuries to other controversial pharmaceutical drugs such as Byetta and Ketek.

According to the Brain Injury Association of America, approximately 1.4 million Americans suffer from a traumatic brain injury each year. The condition has also been deemed the signature injury of the war in Iraq by news organizations and medical professionals. Additionally, thousands of individuals are not treated for their TBI condition, which could cause a worsening of the TBI side effects among patients. It is imperative that an individual who may have suffered from a TBI accident contact a medical professional regarding their potential condition.

Byetta (exenatide) from Amilyn Pharmaceuticals and Eli Lilly was released in 2005, however, the type 2 diabetes drug was allegedly under investigation by the FDA for the potential link to pancreatic inflammation among Byetta patients. In August 2008, approximately six individuals consuming the drug had developed acute pancreatitis and of the six, two had died. Patients of Byetta who are concerned about the potential dangers allegedly associated with the drug are advised to contact a Byetta law firm for more information.

Ketek, which has been available since 2004 from Sanofi-Aventis, has been allegedly linked to the development of liver damage among patients who have consumed the antibiotic that treats upper respiratory infections such as bronchitis and community acquired pneumonia. The FDA is also currently investigating the drug, but those who have been affected by the Ketek side effects are encouraged to contact a medical professional as well as a pharmaceutical attorney.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

Contact Information
LegalView
Katie Kelley
720-226-6613
press-releases@legalview.com
http://avandia.legalview.com

Study Investigates Link Between Genetic Predisposition and Mesothelioma Cancer

LegalView Reports Results of a Breakthrough Study Investigating Link Between Genetic Predisposition and Developing Mesothelioma Cancer

LegalView informed readers to the results of a scientific investigation studying the potential link between genetic components and developing mesothelioma cancer. Scientists determined that genetic responses occurred after a specific type of asbestos was introduced to cells within the lining of the lungs.

Denver, CO, September 01 -- LegalView.com, the number one legal resource available on the Web, offered updated details on its mesothelioma information blog of an advanced scientific investigation studying the link between asbestos and genetics. Researchers, who found a genetic response to a specific type of asbestos known as crocidolite, published their findings in an August 2008 issue of BMC Genetics. The study, a first of its kind, used a methodology of exposing cells within the human lung lining to asbestos and then scientists watched the reaction and changes. The study offers mesothelioma victims a unprecedented look into how asbestos affects the human body. Victims were also provided with a gleam of progress on finding a cure for the condition, although the scientists stated more research is required.

Individuals who are suffering from an asbestos-related disease are advised to contact a mesothelioma law firm that can provide access to a wealth of knowledgeable mesothelioma attorneys. Because mesothelioma cancer is incurable and is commonly considered a preventable illness, discussing the details of a potential mesothelioma lawsuit with a mesothelioma lawyer may provide insight as to how monetary compensation could be awarded to aid in the costly medical bills associated with mesothelioma.

In their study, the researchers reported that asbestosis occurs in nearly 200,000 individuals each year with an additional 4,000 asbestos-related deaths occurring annually as well. Asbestos is a type of mineral that was mined for use in insulation because of its fire-retardant qualities and inexpensive production costs. However, inhaling asbestos fibers has led to a severe and incurable form of lung cancer known as mesothelioma. Millions of Americans may have been exposed to asbestos fibers during the 20th century, as asbestos was heavily mined and often used during the construction of buildings such as elementary schools, universities, hospitals, office buildings, homes and apartments.

In addition to mesothelioma information, LegalView houses a library of other legal issues potentially causing harm to everyday Americans. Also, due to the ongoing crisis among the pharmaceutical community, LegalView has provided updated information on several pharmaceutical drug's side effects and dangers. Among the drugs are Ketek as well as Levaquin and Cipro, both of the fluoroquinolone family.

Ketek (telithromycin) is an antibiotic used to treat conditions such as community-acquired pneumonia, bronchitis, sinusitis and other upper respiratory infections. The antibiotic is manufactured by Sanofi-Aventis and has been available to the market since 2004, however, since its release, the U.S. Food and Drug Administration (FDA) has reported nearly 20 deaths of individuals consuming the medication. The deaths all involved the development of liver damage among the patients who died as well as an additional 100 patients who also reported signs and symptoms of liver disease while taking Ketek. Those who have consumed Ketek and feel they exhibit any of the side effects commonly associated with liver disease, such as jaundice or yellowing of the skin, should seek medical assistance immediately. Additionally, it may be advisable for an individual to be involved with a Ketek class action lawsuit and contacting an experienced pharmaceutical lawyer will assist with any legal action necessary.

Levaquin (levofloxacin) and Cipro (ciprofloaxacin), similar to Ketek, are also antibiotics that treat bacterial infections such as bronchitis, although, in July 2008 the FDA gave all of the fluoroquinolone drugs an increased warning label known as the "black box" warning label, the harshest warning given by the FDA. The warning label was increased because the Levaquin and Cipro risks had been previously linked to tendon rupture among patients, according to several studies including one published in Clinical Rheumatology in February 2004. The black box warning is to encourage physicians to avoid prescribing these drugs to patients who may be at a greater risk for Achilles tendon rupture, including elderly patients.

LegalView provides a vast array of resources for individuals plagued by legal misfortune so that they may positively improve their situation and have the tools necessary to do so, including the recently updated Zimmer Durom cup information portal. The Zimmer Durom cup is an artificial hip component used during hip replacement surgery among patients. However, Zimmer Holdings, manufacturers of the product, recently halted the production of the hip socket after hundreds of doctors complained that the medical device was failing among patients. To learn more about the potential for a Zimmer Durom cup recall, visit the LegalView homepage at http://www.LegalView.com/.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

Contact Information
LegalView
Katie Kelley
720-771-3246
press-releases@legalview.com
www.legalview.com

---

Mesothelioma Treatment Video
Bengoshi-san
Accident Injury Compensation

Visual Reference for Neurosurgeons Published

A Concise and Visual Reference for Neurosurgeons Published in Conjunction with the American Association of Neurological Surgeons

New York, NY, November 26, 2008 -- Every year approximately 30,000 patients in the United States suffer from a ruptured cerebral aneurysm. And according to the American Association of Neurological Surgeons (AANS), up to six percent of the population may have an unruptured one. Managing such a serious medical condition poses significant challenges for patients as well as their treating physicians. Vascular Neurosurgery, co-published by Thieme and the AANS, includes one section devoted to aneurysms and subarchnoid hemorrhage. The book is a step-by-step guide to management, preoperative evaluation, surgical technique, and postoperative management. It is currently the only text in the field that provides concise visual chapters on how to carry out such surgical procedures.

The second edition of Vascular Neurosurgery is a new volume in the classic Neurosurgical Operative Atlas series. This detailed atlas, which offers surgical approaches to common neurovascular diseases and conditions, was developed to "meet the needs of residents and neurosurgeons particularly when it comes to learning how to conduct an operation, brushing up on a technique, or just finding out how others do things," says editor Dr. R. Loch Macdonald, head of the division of neurosurgery at the University of Toronto, in Toronto Ontario.

The book contains more than 300 illustrations that vividly demonstrate surgical steps and techniques. One of the many appealing aspects of the atlas lies in its brevity. Each chapter can be read within thirty minutes, enabling a physician or resident to quickly page through the book prior to surgery.

This practical surgical reference is not only useful for prepping for oral board examinations; it is also an asset to clinicians in neurosurgery and vascular surgery. Vascular Neurosurgery is one in an ongoing series of books co-published by Thieme and the American Association of Neurological Surgeons. The five volume set, edited by leading experts in the field, covers the entire spectrum of neurosurgery. Other titles in the series include, Neuro-Oncology, Spine and Peripheral Nerves, Pediatric Neurosurgery, and Functional Neurosurgery.

About the American Association of Neurological Surgeons

The American Association of Neurological Surgeons (AANS) is the organization that speaks for all of neurosurgery. The AANS is dedicated to advancing the specialty of neurological surgery in order to promote the highest quality of patient care.

About Thieme

Thieme Publishing Group is a privately held scientific and medical publishing house employing more than 950 people and maintaining offices in seven cities, including New York, Delhi, Stuttgart and three other locations in Germany. Founded in 1886, the Thieme name has become synonymous with high quality and excellence in medical and scientific publishing. Today, Thieme is the market leading publisher of neurosurgical content and holds strong market positions in orthopedics, radiology, anatomy and chemistry, among other specialties. Thieme publishes 137 peer-reviewed journals and over 500 new books annually. The company also has a rapidly growing array of web-based products in medicine and science. Popular online products include Thieme eJournals and the Thieme Electronic Book Library, which are accessible via thieme-connect.com, Thieme's platform for electronic products. New anatomy resources include the thiemeteachingassistant.com for faculty, and winkingskull.com for students. Please visit thieme.com for additional information.

Contact Information
Thieme Publishers
Bettina Ziegler
+49-711-8931-488
bettina.ziegler@thieme.de
www.thieme.com

---

Manufacturing Simulation Software
Steam Shower Saunas
Heat Pump Technology
Mesothelioma Prognosis

Market Growing For Surgical Sealants, Glues, Wound Closure, and Anti-Adhesion Products

Surgical Sealants, Glues, Wound Closure, Anti-Adhesion, Worldwide; MedMarket Diligence Report

MedMarket Diligence tracks wound closure, hemostasis and anti-adhesion technologies and forecasts this market in a forthcoming worldwide report, with insight into market introduction, growth, competition and business opportunity.

Foothill Ranch, CA, November 18, 2008 -- Opportunities for products in wound closure, hemostasis and anti-adhesion products are plentiful for established and emerging companies, driven by innovation in product formulation and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America and other markets globally.

MedMarket Diligence monitors and identifies emergence and growth of novel technologies in wound closure, hemostasis and anti-adhesion and applies its industry awareness and analysis to providing insight into market introduction, growth, competition and opportunity worldwide. The products, current and forecast markets, companies and opportunities are detailed in this 2008 report from MedMarket Diligence. The report details the markets worldwide, with detailed geographic segmentation, for surgical sealants, glues, hemostats, sutures, tapes, and other wound closure technologies, as well as products for the prevention of post-surgical adhesion.

"The use of these biologicals and other product forms, once representing a minor share of wound closure, has now moved into the mainstream, with sealant, closure, hemostasis and combinations of uses by these products eclipsing use by traditional wound closure devices," says Patrick Driscoll, president of MedMarket Diligence. According to Driscoll, the market is also experiencing increased competition and market evolution as new products are introduced and some consolidation is taking place even while the number and types of procedures target by these products proliferate. A number of market leaders have solidified their positions within the surgical closure and securement markets through successful internal development programs and through technology partnerships with innovative vendors of next generation technologies.

MedMarket Diligence's comprehensive analysis of the market for surgical sealants, glues/adhesives, hemostats, tapes, sutures, and anti-adhesion products is a worldwide report that is a must have tool for market planning, strategic analysis and positioning in this large and growing market. The report details the products on the market, their current and forecast penetration of clinical application, new products under development and their status, the current and forecast market for products by major country markets worldwide, and the current and hopeful competitors in the market and their positions, strengths and strategies. The report provides specific forecasts and shares of the worldwide market by segment for the U.S., Europe (United Kingdom, Germany, France, Italy, BeNeLux), Latin America, Japan and Rest of World.

The report is scheduled for publication in early December 2008. The report is described with table of contents (list of exhibits pending) at http://mediligence.com/rpt/rpt-s175.hm. A pre-paid discount is available and the report may be purchased at https://www.mediligence.com/store/page29.html or via order form (http://www.mediligence.com/order_forms/s175_order.pdf).

Contact Information

MedMarket Diligence, LLC
Patrick Driscoll
949-859-3401
patrick@mediligence.com
www.mediligence.com

---

Compulsive Gamer
Validation Company
Accident Lawyer Minneapolis
Lower Back Pain

Charity Helps Millions Left Starving by Health Insurance

Local Charity Helps "Feed" the Millions Left "Starving" by Health Insurance

Manna Scholarship Fund was formed in 2007 as a 501(c)3 organization focused on filling the funding gap for individuals needing inpatient eating disorder treatment. Because insurance policies will rarely cover the cost of successful inpatient treatment, MSF is attempting to "fill the funding gap" for those in need of treatment. Manna Scholarship Fund is hosting a fundraising dinner "Manna in Motion" to promote the scholarship fund and to raise awareness of this great need to the public.

Atlanta, GA, September 11, 2008 -- Who: Manna Scholarship Fund was formed in 2007 as a 501(c)3 organization focused on filling the funding gap for individuals needing inpatient eating disorder treatment.

Why: Because the Health Insurance industry does not understand the significance of adequate eating disorders treatment, insurance policies will rarely cover the cost of successful inpatient treatment. This cost can be between $800-$2000 a day, with appropriate treatment ranging from 60-90 days, and often longer. This puts families of these sufferers in grave danger. Statistically, this illness is extremely significant because "anorexia has the highest premature fatality rate of any mental illness" (Sullivan, 1995). Without assistance, those in need of this type of inpatient treatment will have no other option but to pay the full price of treatment.

Being awarded a Scholarship from the Manna Fund provides the scholarship winner with:

· An active role in the choosing the treatment facility
· The opportunity to receive adequate, life-saving care
· Options to extended treatment that previously weren't available through the health insurance and/or to patients that have no inpatient benefits
· A greater chance of recovery due to access to the In-Patient services
· The opportunity to gain wholeness and in turn give back to others in need.

How: In order to provide adequate eating disorder treatment for those in need, Manna Scholarship Fund seeks to raise funds through many avenues, including in-kind donations, outreach programming that focuses on family investment (jewelry-making parties, bowling tournaments), corporate sponsorships, and grants. Manna Scholarship Fund has raised nearly $100,000 for scholarships in the past year and a half, supplying three individuals with the necessary inpatient treatment and reaching a hundred families through outreach. As the word has gotten out about the existence of this fund, scholarship application submission has sky-rocketed.

What/When: In order to contribute to this need, Manna Scholarship Fund is hosting a fundraising dinner "Manna in Motion" to promote the scholarship fund and to raise awareness of this great need to the public. This event will be held on Thursday, September 25th at the 1420 Room at 1420 Dunwoody Village Parkway, Dunwoody, Georgia.

At this event, guest speaker, Barbara Gaby of the Gaby Foundation, will discuss her journey through her own eating disorder as well as what it was like to be a part of a prominent family while enduring an eating disorder. Guests will also hear from Genie Burnett, the Executive Director of the MSF, in regards to the mission and vision of the MSF, as well as outreach and ongoing fundraising efforts. Guests will also be entertained by surprise performances as well as a jazz quartet. In efforts to raise funds for MSF, Manna in Motion will also hold a silent auction.

For more information about the Manna Scholarship Fund and the upcoming fundraising event, please go to www.mannafund.org, or contact Jesse Stanford at jstanford@mannafund.org or @ (404)-665-7725 The Manna Scholarship Fund, Inc. 2250 Satellite Blvd, Suite 100, Duluth, GA 30097.

Headliners:

· Up to 10 million people each year suffer from eating disorders while their health insurance leaves them paying the bills.
· Without treatment up to 20% of people with serious eating disorders die. With treatment that number falls to less than 3%.
· A local charity Manna Scholarship Fund bridges the gaps in patient's ability to pay for necessary treatment.
· Founded by Dr. Genie Burnett and Leslie Cox RD, LD in 2007, the Manna Scholarship Fund focuses on education, awareness, and action in offsetting the exorbitant cost of treatment.
· Recognizing the hidden "holes" in the typical health insurance coverage, Dr. Burnett and Mrs. Cox chose to go about fixing the problem the only way they knew how and not with the indifference that the Health Insurance Industry displays.
· The huge number of potential recipients that could benefit from a scholarship is simply so big that the Scholarship Fund needs your donations.

Contact Information

Manna Scholarship Fund, Inc
Dr. Genie Burnett, Executive Director
(404)-665-7725
info@mannatreatment.org
www.mannafund.org
770-495-9775

Laser Hair Removal Threatened by Common Dangers

New Route to Hair Free Skin - But Are You At Risk of Serious Complications?

In the USA in 2007 nearly 1.5 mil. laser hair removal procedures were carried out. Shockingly a staggering 19.9% of patients undergoing these procedures experience complications. LaserHairRemoval-Info.com was founded in 2005 to provide consumers with little-publicized information on laser hair removal, and is launching a new book aiming to bring the knowledge needed by consumers out from behind the locked doors of the laser clinics and places it firmly in the hands of those that need it.

New York, NY, September 12, 2008 -- Success of Laser Hair Removal Threatened by Increasingly Common Dangers and Widespread Ignorance.

The removal of unwanted hair using lasers is becoming increasingly commonplace; in the USA in 2007, nearly 1.5 million laser hair removal procedures were carried out1 and shockingly a staggering 19.9% of patients undergoing these procedures experience complications2.

Increasingly consumers are having to take their fate into their own hands and perform the research and investigation necessary to ensure that they receive the appropriate treatment rather than relying on the dubious expertise of some of the laser hair removal clinics, many of which are not operating under the direct supervision of a qualified doctor or dermatologist.

"I never want to go near a laser again," says former laser hair removal patient Andrea (age 43) of Brooklyn, New York. After undergoing treatments totaling $2,900 in cost over the course of a year, Andrea has now reverted to shaving her unwanted body hair as the treatment was almost completely ineffective. "The wasted money, although it is a lot of money to me, is irrelevant compared to what I have suffered in pain and embarrassment undergoing treatment after treatment which initially had no effect at all and then when the laser strength was increased resulted in sore, unsightly burns."

Now a brand new report has been created, aimed squarely at consumers who want to get laser hair removal without the risk of side effects or ineffective treatment. Readers can download this free insider report, Top 10 Must-Know Tips on Laser Hair Removal, from http://www.laserhairremoval-info.com/download/booklet.htm. This no-nonsense guide will help patients to avoid the fate experienced by Andrea and ensure that they get the right laser hair removal treatment for their specific circumstances.

"Be prudent and selective when evaluating your options for any possible cosmetic procedure," advises dermatologist Gary Monheit, MD, president of the ASDS.

Patients must realize that just because a laser clinic near their home is offering treatment for a good price doesn't mean that this particular clinic possesses the expertise or the equipment to safely and effectively treat their skin type. The knowledge offered in the newly published book: Insider Secrets of Laser Hair Removal (available from September 2008) gives consumers the ability to understand the whole process of laser hair removal and how it will apply to their own physiology and specific goals.

LaserHairRemoval-Info.com was founded in 2005 to provide consumers with little-publicized information on laser hair removal. The site offers a range of articles, research materials and message forums for people considering this life-changing treatment.

Contact Information
LaserHairRemoval-Info.com
Ingrid Preube
49-531-577497
ingrid@laserhairremoval-info.com

 

Innovative Senior Services Company Launched

New Innovative Company Launch - Opt2Care, Senior Services

Opt2Care, Senior Services launches a new and innovated senior home care company in New Jersey.

East Orange, NJ, September 12, 2008 -- Opt2Care Senior Services is not another home care company. The difference is in the founder's commitment, services provided, and the quality of staff that provide senior care services.

Collectively, the founders, Melissa Louie and Gerry Sayco, have over 20 years of relevant health care industry experience.  Melissa Louie, LMSW, MPA, has worked in the healthcare field since 1992. Her passion to make a difference in the field of aging stems from her close relationship with her grandmother. While caring for her grandmother, she recognized the need for competent and compassionate clinicians in the field of aging. For the past 13 years, she has worked diligently to improving the quality of life for older adults and their families.  For example, Melissa was employed as Program Director at Chelsea Adult Day Health Center; Eldercare Coordinator for Catholic Charities; and as a Medical Social Worker at Dry Harbor Nursing Home.

Gerry Sayco is an accomplished results-oriented business professional with over 12 years of operational excellence within the Pharmaceutical Industry. Gerry's close relationships with senior family members and friends of family helped him identify what was lacking in existing home care options and prompted him to pursue a home care service with "real" alternatives for today's world. Gerry expressed his strong dedication to this service by stating, "my goal is not only to apply the experiences and guidance I have received from mentors' within my career and family, but also to make a revolutionary difference in the Senior Home Care market."

Opt2Care (acronym for "Opt To Care") helps older adults achieve optimum health and well-being by blending traditional home care services and complementary therapies. Factors that contribute to the healing of the body, mind, and spirit are addressed.  Complementary therapies include art, music, massage, Reiki, and Care Management.

Opt2Care encourages a collaborative team approach and employs only experienced practitioners and care providers that are dedicated to providing quality service that will help seniors remain independent in the community.

Opt2Care, Senior Services
PO Box 594, Eatontown, NJ 07724
888-678-2243
www.opt2care.com

Contact Information
Opt2Care
Gerry Sayco
888-678-2243
Contact@Opt2Care.com
www.opt2care.com

Medical and Practice Management Suite Client/Server Receives CCHIT Certification

LSS Data Systems' Medical and Practice Management (MPM) Suite Client/Server 5.54 Receives 2007 CCHIT Certification

Software Complies with 100 Percent of Updated 2007 Certification Criteria

EDEN PRAIRIE, minn.-- July 02, 2008 --The Certification Commission for Healthcare Information Technology (CCHIT®) announced yesterday that LSS Data Systems' product Medical and Practice Management (MPM) Suite Client/Server 5.54 is CCHIT Certified®, and meets the Commission's ambulatory electronic health record (EHR) criteria for 2007. Ambulatory EHRs are designed for physician offices and clinics where most Americans get their healthcare. CCHIT - an independent, nonprofit organization - is the Recognized Certification Body in the United States for certifying health information technology products.

In the second year of the program's operation, the criteria and testing have been significantly enhanced. The Commission added 96 criteria to the 151 original requirements from last year. Medical and Practice Management (MPM) Suite Client/Server 5.54 has been tested and passed inspection of 100 percent of a set of updated criteria for functionality, interoperability and security.

"For 2007, the Commission raised the bar from the previous year's criteria. Ambulatory EHRs now must include electronic prescribing, demonstrate an ability to receive lab results, and show enhanced patient safety, quality, and security features," said Mark Leavitt, M.D., Ph.D., chair, CCHIT. "Investment in 2007 certified ambulatory EHRs gives providers even more powerful tools to improve quality, safety and efficiency while protecting the privacy of health information."

The CCHIT Certified mark - a "seal of approval" for EHR products - provides the first consensus-based, government-recognized benchmark for ambulatory EHR products. By looking to products with the CCHIT Certified seal, physicians and other providers can reduce their risk in selecting an EHR product, allowing them to focus their evaluation on the special needs of their practices.

"This certification illustrates our ongoing commitment to provide the highest quality software for our customers. CCHIT certification is definitely something our customers value," said Bill Schmidt, Vice President of Sales & Corporate Development at LSS Data Systems. "We are delighted with the achievement of this milestone. We take pride in the strength of our products and the foundation of our seamless integration with MEDITECH to create one electronic health record across the health care enterprise."

LSS customer Parkview Adventist Medical Center, based in Brunswick, ME, recently updated to MPM Client/Server Version 5.54. "We congratulate LSS for 2007 certification of the MPM Suite," said Bill McQuaid, Chief Information Officer at Parkview. "One of Parkview's main approaches to care involves utilizing state-of-the-art technology to provide the highest quality care. It is important to us to use products which we know meet and exceed industry benchmarks."

CCHIT's certification compliance criteria and its design for a certification inspection process have been thoroughly researched, taking into account the state of the art of EHRs and available standards, and comparing certification processes in other industries and other countries. The inspection process is based on real-life medical scenarios designed to test products rigorously against the clinical needs of providers and the quality and safety needs of healthcare consumers and payers. One script, for example, recreates a scenario of an elderly man with poorly controlled diabetes, hypertension and other chronic conditions in order to test EHR functions such as potential adverse drug reactions, disease management and treatment plans.

About LSS Data Systems

LSS Data Systems, a MEDITECH partner founded in 1982, develops clinical, financial and administrative solutions for medical practice groups, healthcare delivery systems and clinics across the United States and internationally. Together with MEDITECH, LSS has developed the Medical and Practice Management (MPM) Suite, a full-featured ambulatory care solution that integrates physician practices and clinics with MEDITECH's Health Care Information System. The MPM Suite includes an ambulatory Electronic Health Record with prescribing/ordering, physician documentation, scanning, scheduling, billing and financial management tools. For more information please visit www.lssdata.com.

About CCHIT

The Certification Commission for Healthcare Information Technology (CCHIT®) is an independent, nonprofit organization that has been named by the federal government as the Recognized Certification Body for health information technology. Its mission is to accelerate the adoption of health information technology by creating a credible, sustainable certification program. The certification requirements are based on widely accepted industry standards and involve the work of hundreds of expert volunteers and input from a variety of stakeholders throughout the health care industry. More information on CCHIT and CCHIT Certified® products is available at www.cchit.org.

"CCHIT®" and "CCHIT Certified®" are registered marks of the Certification Commission for Healthcare Information Technology.
Contacts

LSS Data Systems
Megan Salmela, 952-941-1000
msalmela@lssdata.com
or
CCHIT
Sue Reber, 503-703-0813
sreber@cchit.org

Cancer Institute Receives Grant to Study Long-term Health Effects of Traumatic Brain Injuries

John Wayne Cancer Institute Receives Grant to Study Long-term Health Effects of Traumatic Brain Injuries

Research Will Focus on Relationship of Concussion, Pituitary Hormonal Failure and Quality of Life in Retired National Football League Players

SANTA MONICA, Calif.-- July 02, 2008--The John Wayne Cancer Institute at Saint John's Health Center announced today that it has received a grant from the National Operating Committee on Standards for Athletic Equipment to study pituitary hormonal failure (hypopituitarism) in retired football players.

The research, which will be conducted in collaboration with the University of North Carolina's (UNC) Department of Exercise and Sport Science, and the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, will be directed by Daniel F. Kelly, MD, director of the Neuro-Endocrine Tumor Center at the John Wayne Cancer Institute, and Kevin M. Guskiewicz, PhD, chairman of the Department of Exercise and Sport Science at UNC.

In a cohort of retired National Football League (NFL) players, the study will examine the relationship between the number of concussions sustained in players' NFL careers, and their subsequent pituitary hormonal function and post-retirement quality of life. The investigators hypothesize that players sustaining multiple concussions are at increased risk of developing pituitary hormonal dysfunction which may in turn contribute to problems of obesity, fatigue, impaired metabolism, depression, sexual dysfunction and a general poor quality of life.

According to Dr. Kelly, the new study will focus on a relatively unexplored area of traumatic brain injury (TBI)-the potential correlation between recurrent concussions and pituitary hormonal dysfunction. More than 1.2 million Americans sustain a TBI annually, the majority of which are cerebral concussions. Repeat concussions have been shown to be a risk factor for neurodegenerative dementing disorders, including mild cognitive impairment and Alzheimer's Disease. However, little is known about the impact of single or multiple concussions on hormonal function and quality of life. Only in the sport of boxing, have a few small studies shown that boxers are at increased risk of developing pituitary failure. In contrast, it is well known that a single severe head injury can lead to pituitary damage and hormonal abnormalities in up to one third of individuals.

The pituitary is a small bean-shaped gland located immediately below the brain and behind the nasal cavity in the skull base; it is connected to the brain by the thin delicate vascular pituitary stalk. Weighing less than one gram, the pituitary is often called the "master gland" since it controls the secretion of the body's hormones. These essential substances when released by the pituitary into the blood stream have a broad range of effects on growth and development, sexuality and reproductive function, metabolism, the response to stress and overall quality of life.

"This research is long overdue," Dr. Kelly said. "Millions of young people and professional athletes participate in sports that put them at risk of concussion; not just football, but also hockey, rugby, soccer, baseball and basketball. We need to know more about how these so-called "minor head injuries" impact their lives in subsequent years, and in particular, whether multiple concussions can lead to pituitary hormonal failure and poor quality of life."

Using the database of the Center for the Study of Retired Athletes at University of North Carolina and in cooperation with the National Football League Players' Association, 90 study participants will be categorized based on the number of concussions they sustained during their NFL career. The retired players will then be assessed utilizing pituitary hormonal blood tests, body composition testing and neurobehavioral, quality of life and sexual function surveys. Retirees found to be deficient in any hormones such as thyroid, testosterone or growth hormone will be treated with physiological replacement doses of the appropriate hormone and will then have repeat quality of life testing. Hormonal testing assays will be conducted by the General Clinical Research Center at Harbor-UCLA Medical Center under the direction of Professor Christina Wang, an endocrinologist and a study co-investigator.

"The problem of sports-related concussions is increasingly recognized as a major contributor to long-term disability in many retired athletes," said Bob Klein, vice president at Saint John's Health Center and a ten-year NFL veteran with the Los Angeles Rams and San Diego Chargers. "However, the potential impact of concussions on quality of life is not well understood. This research will fill that gap in our knowledge. I have spoken with many of my former colleagues in the NFL, and they share my belief in the critical importance of this study."

The Neuro-Endocrine Tumor Center (www.neuro-endo.org) is housed at Saint John's Health Center and the John Wayne Cancer Institute in Santa Monica, California. The Center's focus of activities is the treatment of pituitary tumors, brain tumors, and other neuro-endocrine disorders including pituitary hormonal deficiencies.

The Center for the Study of Retired Athletes at the University of North Carolina works in close affiliation with the National Football League Players Association. Since 2001, the Center has been investigating a spectrum of physical and mental disabilities common to retired athletes. The research team will begin work in July 2008, with initial research results expected in 2010.

Since its founding in 1942 by the Sisters of Charity of Leavenworth, Saint John's Health Center has been providing the patients and families of Santa Monica, West Los Angeles and ocean communities with compassionate, advanced medical care. Saint John's provides a spectrum of treatment and diagnostic services with distinguished areas of excellence in cancer care, cardiac care, orthopedics and women's health. Saint John's Health Center is also dedicated to bringing to the community the most innovative advances in technology and patient care available in a healing environment.

Since 1981, the John Wayne name has been committed by the Wayne family to groundbreaking cancer research in memory of the much-loved actor who died of cancer. The John Wayne Cancer Institute has received worldwide acclaim for advances in understanding the disease, focusing on melanoma (skin cancer), breast, prostate, colon, pancreatic, lung and liver cancer, as well as lymphoma and leukemia. With its unique ability to rapidly turn scientific breakthroughs into innovative approaches to treatment and early detection, JWCI provides immediate hope to cancer patients from around the globe.
Contacts

Saint John's Health Center
Greg Harrison, 310/829-8010
858/472-5560 (cell)
gregory.harrison@stjohns.org

Mesothelioma Survival Rates Among Patients Taking New Treatment

LegalView Recounts the Results of a Recent Mesothelioma Study That Reported High Survival Rates Among Patients Taking New Treatment

LegalView reported the results of an Italian study to its mesothelioma blog readers; the results detailed a positive outcome and increased survival rate for elderly pleural mesothelioma victims. The study, recently published in a British medical journal, used a combination of two medicinal treatments commonly prescribed separately.

Denver, CO, August 16, 2008 -- LegalView, the most comprehensive legal resource available on the Web, recounted the results of an Italian study to its mesothelioma information blog readers. The study attempted to increase the survival rate of elderly pleural mesothelioma patients by combining two medications: Alimta (pemtrexed) and Paraplatin (carboplatin). The results of the study were released in a June issue of the British Journal of Cancer and the conclusions detailed the highly-effective treatments, which increased the survival rate among pleural mesothelioma patients 65 years of age or older.

Mesothelioma is an incurable cancer that is often attributed to the inhalation of asbestos fibers and dust containing tremolite. Asbestos is a known carcinogen, according to the Environmental Protection Agency (EPA), which is responsible for regulating the cleanup of the hazardous material. Asbestos was often prized for its ability to remain fire-resistant, while being produced cheaply, and served as a key ingredient in many products including insulation that was implemented into homes, apartment complexes, universities, schools, business offices and hospitals around the country. Individuals who suffer from mesothelioma cancer are advised to speak with a knowledgeable mesothelioma attorney in order to better educate themselves on the possibility for developing a mesothelioma lawsuit. Due to the extremely costly medical bills associated with increasing survival rate among mesothelioma cancer victims, developing litigation may result in monetary compensation to assist with those medical bills.

LegalView not only offers resources on the most recent mesothelioma news and clinical trials, but also offers information on a variety of other legal issues afflicting millions of Americans. Most recently, LegalView updated several of its pharmaceutical drug information portals with news on updates and recalls; some of the portals include Viapro, Ketek and the Zimmer Durom cup.

The development of the Viapro information portal occurred after the U.S. Food and Drug Administration (FDA) issued a press release on the recall of the drug because of contamination of a harmful chemical known as thiomethisosildenafil. The male sexual-enhancement prescription drug, manufactured by EG Labs, is used to treat erectile dysfunction (ED). The undeclared ingredient may be harmful to patients especially when interacting with nitrates found in other prescription drugs. The Viapro recall occurred because the drug may cause dangerously low levels of blood pressure among patients also taking nitroglycerin for diabetes, high blood pressure, high cholesterol or heart disease.

Ketek, which is an antibiotic used to treat upper respiratory infections such as pneumonia, bronchitis and sinusitis, had its warning labels increased recently due to the threat of liver disease among patients consuming the drug. To learn more about the Ketek side effects, visit http://ketek.legalview.com/.

Also among the recently updated information portals is that of the Zimmer Durom cup. Zimmer Holdings has ceased production of its Durom cup because of complaints that the hip socket was failing among many patients. Although the company has ceased production of the hip socket, pending internal investigations into the potential failure, the hip socket has already been used in over 12,000 hip replacement procedures since its introduction to the market in 2006. Patients who may be at risk for the Durom cup failure should seek medical attention immediately to ensure no further damage occurs.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

Contact Information
LegalView
Katie Kelley
720-771-3246
press-releases@legalview.com
www.legalview.com

Industry Makes Request to Decrease Asbestos Regulations

LegalView Offers Mesothelioma Blog Readers Details of Disconcerting Request to Decrease Asbestos Regulations from Industry

LegalView informed mesothelioma blog readers of an potentially troubling request by automotive, chemical and mining industries' paid researchers to "water down" asbestos regulations. The industry-hired scientists argued that asbestos is no longer as dangerous, even though several international health organizations have declared no safe level of the material.

Denver, CO - August 2, 2008 -- LegalView, the number one resource for everything and anything legal on the Internet, recently updated readers with the latest piece of mesothelioma information, relating to the request by paid researchers for the automotive, chemical and mining industries to decrease asbestos regulations. In a July 2008 summit in Washington D.C., the Environmental Protection Agency (EPA) met with the Office of Solid Waste and Emergency regarding the request. The industry researchers argued that asbestos fibers found in sand, taconite and other materials are less toxic than originally deemed in the 1980s when the regulations were created. However, the EPA along with the International Agency for Research on Cancer, the Occupational Safety and Health Administration (OSHA) and The World Health Organization (WHO) have all determined that no level of exposure to asbestos fibers is safe and the material as well as products using asbestos should be permanently banned.

Asbestos was mined for years and was frequently used in the construction industry for an array of products, most often insulation. However, it was determined that exposure to asbestos fibers causes a deadly form of lung cancer known as mesothelioma. Individuals who suffer from mesothelioma cancer should contact an experienced mesothelioma attorney to receive a legal consultation on the possibility of developing a personalized mesothelioma lawsuit. Because the cancer is fatal and no completely effective mesothelioma treatment exists to reduce the disease it may be important to develop litigation and potentially receive monetary compensation to pay for costly medical bills. Mesothelioma is a dormant condition that can take decades before symptoms reveal themselves, at which point, little can be done to improve the illness.

According to news reports, at the Washington D.C. summit, approximately 83 public health officials signed a 29-page report on the "science-for-hire" practice, which Dr. Michael Silverstein, who wrote the report, alleges is occurring on the part of automotive, chemical and mining industries. The report, opposing the request, urged the EPA to focus on public health rather than big industry and to avoid decreasing the asbestos regulations.

Learn more about this ongoing issue as well as other legal issues through LegalView.com. LegalView continues to maintain a comprehensive library of legal issues; issues that may be causing harm to millions of Americans each year. LegalView recently updated several of its issues to include detailed information and news. Some of the recently updated sites include information on the Zimmer Durom cup, the Ketek antibiotic and Avandia prescriptions.

The Durom cup, manufactured by Zimmer Holdings, is an artificial hip component that has been under fire by physicians who have said the device is failing their patients. Because of the alleged Zimmer Durom cup risks, the company has ceased manufacture of the hip socket. However, since production began in 2006, nearly 12,000 patients received the cup and may be affected by the failing hip socket and should contact a knowledgeable attorney for advice about the potential Durom cup recall.

Ketek is a pharmaceutical prescription antibiotic that is used to treat upper respiratory infections including pneumonia or bronchitis. Reports have tied the antibiotic with the possibility of severe liver damage among patients. Additional Ketek side effects may also be considered dangerous and those who report signs of yellowing skin or jaundice should consult a doctor immediately

The Avandia portal is continually being updated to provide the public with extensive research, scientific findings and experienced attorney links. Avandia is a prescription drug used to treat type 2 diabetes, which currently affects millions of individuals in the United States. Recent research, however, has found a disturbing link between the use of Avandia and an increase of heart disease as well as osteoporosis among patients. Individuals who feel they may have symptoms relating to heart disease or who have suffered from a bone fracture likely induced by the Avandia side effects, should speak with a medical expert immediately. Additionally, it is advisable to locate an experienced pharmaceutical law firm in case legal advice is necessary for an Avandia settlement.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

CONTACT INFORMATION
Katie Kelley
LegalView
720-226-6613

Alan Haburchak
LegalView
720-226-6613

Revolutionary HIV Testing Bill Passes

Bill to 'Revolutionize' HIV Testing Passes California Legislature Unanimously

AB 2899 (Portantino, D-Pasadena), Sponsored by AIDS Healthcare Foundation (AHF), Overhauls Counseling Model for HIV Testing Programs; Bill Eliminates Outdated 'One Size Fits All' Approach for More Prudent Public Health Approach

SACRAMENTO, Calif.-- August 12, 2008 --AIDS Healthcare Foundation (AHF), the operator of the largest non-government HIV testing program in California, today praised the California Legislature for its passage this week of Assembly Bill 2899 (Portantino, D-Pasadena).

"AB 2899 will revolutionize the way we do HIV testing in California, and we strongly urge the Governor to sign this bill," said Michael Weinstein, President of AIDS Healthcare Foundation. "Today, in government-funded programs, extensive education and counseling is required for every person regardless of how many times they might have been tested. Treating the young person, who is testing for the first time the same as a person in their forties or fifties who has been tested dozens of times doesn't make sense. This important reform will allow AHF, the largest HIV tester in California, to do three times as many tests per hour as we do now. The unanimous approval of the legislature for this common sense approach to HIV testing is very encouraging."

The bill, known as the Sexually Transmitted Diseases and HIV/AIDS Counseling Reform Bill, unanimously cleared both chambers of the Legislature this week-clearing the California Assembly (64-0) earlier today after clearing the Senate in a 36 to 0 vote yesterday.

"This bill brings the requirements for HIV counseling in line with where we are today in our knowledge and understanding of HIV/AIDS and other STDs, and it will allow us to focus our counseling efforts where they are most needed-to those at high risk and those who may test positive," said Joey Terrill, Acting Director of Public Affairs for AIDS Healthcare Foundation, co-sponsor of the bill. "The California Legislature has recognized the importance of this prudent public health legislation with its unanimous passage in both chambers. When this bill is chaptered into law, it will allow the Department of Public Health and the State Office of AIDS far more flexibility in its counseling regulations to best serve and reflect the needs of communities throughout California."

AB 2899 codifies the changes that testing organizations need to conform their practices to current needs and to facilitate the swift introduction of newer counseling models by the Office of AIDS.

About AHF

AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS healthcare provider. AHF currently provides medical care and/or services to more than 80,000 individuals in 20 countries worldwide in the US, Africa, Latin America/Caribbean and Asia. Additional information is available at www.aidshealth.org
Contacts

AIDS Healthcare Foundation
Ged Kenslea, 323-860-5225
Mobile: 323-791-5523
gedk@aidshealth.org
or
Lori Yeghiayan, 323-860-5227
Mobile: 323-377-4312
lori.yeghiayan@aidshealth.org

Families Informed About Insurance Coverage With Medical Reimbursement Resource

Medical Reimbursement Resource LLC of Houston Helps Families Stay Informed, Choose Right Insurance Coverage

Company Educates Consumers of Medicare Part C Advantage Plan Enrollment Period Deadline - March 31, 2008

Houston, TX  -  March 12 -- Medical Reimbursement Resource (MRR) LLC, a leading patient advocacy company in Houston, advises the Medicare community of March 31st Medicare Part C enrollment deadline and helps educate consumers on the best health insurance choices for their situation.

MRR professionals explain that the Medicare program is a federal program that helps senior citizens and other qualifying individuals pay for health care. Divided into parts, A, B, C, and D, Part C is an alternative to Parts A and B. Under Part C, private health insurance companies can contract with the federal government to offer Medicare benefits through their own policies.

"Medicare Part C Advantage Plans are not for everyone. Generally the choice of providers is more limited than with traditional Medicare Parts A & B. Individuals with special health problems and working with physicians that are important to them are recommended to remain on Medicare Parts A and B," said MRR owner Jane Lehto.

"However, it's great to have another insurance option available for Medicare beneficiaries. This is where Medicare Part C comes in," Lehto added.

Lehto and her staff help clients choose the right insurance coverage and receive all benefits to which they are entitled under their particular policy. With over 40 plans from which to choose in Texas, it is an often difficult process through which to navigate for the unknowing consumer.

Lehto further explained that the type of candidates qualifying for the Medicare Part C, particularly the Medicare Part C Advantage Plus plan, would be those in fragile health and on fixed incomes. The relatively new plans include either HMO's or PPO's and come with modest premiums. A vast number of physicians and hospitals participate in the plans.

"And effective this past January is the option for those switching from Medicare Parts A and B to return to their plans for whatever reason during the enrollment period from November 15 through December 31, 2008," said Lehto.

MRR also assists patients and their families with problem health insurance claims and medical bills, benefit issues, along with insurance choices and a myriad of issues that the consumer faces in today's challenging and complex insurance world. To learn more about Medical Reimbursement Resource LLC, call 1-713-526-0955 or log onto www.mrrmedical.com today.

Press Contact: Philip O'Hara
Company Name: Medical Reimbursement Resource LLC 
Texas Phone: 713-526-0955
Website: www.mrrmedical.com

Predicted Increase in Female Mesothelioma Victims

LegalView Informs Mesothelioma Blog Readers of a Predicted Increase in Female Mesothelioma Victims

LegalView updated readers to an alarming prediction by researchers who said the number of female mesothelioma victims may increase within the next few years. Researchers said that asbestos in hair dryers that were previously unregulated may be the cause.

Denver, CO - July 21, 2008 -- LegalView, the most comprehensive legal resource on the Web, reported on its mesothelioma information blog a potential increase of mesothelioma cancer victims within the next few years, particularly among women, according to researchers. In 1979, the U.S. Consumer Product Safety Commission (CPSC) released information regarding 26 companies and manufacturers of hand-held hair dryers that had been made with asbestos. While the 26 companies had voluntarily taken action to correct the asbestos-containing hair dryers, individuals who had used the tainted hair dryers may be at risk for developing mesothelioma and should consider contacting a mesothelioma lawyer for information on the development of a potential mesothelioma lawsuit.

Mesothelioma is a deadly form of lung cancer that is caused through the inhalation of asbestos fibers. While asbestos was largely used in the construction industry, commonly within insulation, it has also been used in other products including hair dryers. While the hair dryers were corrected and became asbestos-free nearly 30 years ago it is common for mesothelioma to remain dormant for years and even decades, which is why researchers are concerned with a new group of individuals becoming afflicted by mesothelioma and symptoms becoming prevalent now. Researchers are also particularly concerned for women because women allegedly use hair dryers more than men. To learn more about developing litigation, contact a mesothelioma law firm or mesothelioma attorney to better understand the potential for developing an asbestos-related lawsuit and receiving monetary compensation for the costly bills usually associated with a mesothelioma cancer diagnosis.

In addition to information on mesothelioma, LegalView also offers details on a plethora of other legal issues afflicting millions of Americans each year. For example, readers can learn about the latest fluoroquinolones black box warning labeling. Fluoroquinolones are a group of antibiotics that have become increasingly at risk for severe side effects. Of the fluoroquinolones group, the most commonly prescribed drugs are Levaquin and Cipro. Levaquin, also known as levofloxacin, is manufactured by Ortho-McNeil and treats bacterial infections, specifically treating infections such as skin infections, chronic bacterial prostates, urinary tract infections, pneumonia, bronchitis and acute pyelonephritis caused by Escherichia coli (E. coli). The drug, which was released in 1996, has been the center of numerous clinical trials and studies because of the possible Levaquin side effects, which can include the most serious - Achilles tendon rupture - as well as jaundice, seizures, hallucinations, abdominal tenderness and limb numbness.

Similar to Levaquin is Cipro (ciprofloxacin) from Bayer A.G., which was approved for market use in 2000 and is used to treat bacterial infections similar to those treated by Levaquin. The Cipro risks are the same as Levaquin, which is an increased risk of tendonitis. Additionally, Cipro has other side effects that may also be harmful to patients. Some of the side effects include seizure, difficulty breathing, depression, suicidal thoughts, blacking out and hallucinations.

LegalView also has information on other controversial prescription drugs including Avandia. Avandia is a type 2 diabetes drug that has recently been linked to severe risks among patients. The Avandia dangers may include an increased risk of heart failure as well as a higher risk of developing early onset osteoporosis. Patients who may have developed either of these side effects while taking Avandia should speak with an experienced pharmaceutical lawyer to better understand the potential for developing a potential Avandia lawsuit.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/.

Foundation Funds Follow-up Care in Revolutionary Cancer Vaccine Study

Onyx and Breezy Foundation Funds Follow-up Care in Revolutionary Cancer Vaccine Study

The Onyx & Breezy Foundation recently funded after-care for dogs engaged in a revolutionary research study to develop a cancer vaccine that may be given to both humans and animals when successful. The study is being conducted at The Matthew J. Ryan Veterinary Hospital, a small animal teaching hospital affiliated with the University of Pennsylvania in Philadelphia.

Tuxedo Park, NY and Philadelphia, PA  -  March 14 -- The Onyx & Breezy Foundation has announced a gift to The University of Pennsylvania School of Veterinary Medicine. The gift will cover the expense of follow-up care for 12 dogs that are currently enrolled in the School's cancer vaccine study.

"Thanks to this generous gift, more participants in our lymphoma cancer vaccine clinical trial will be able to return for follow-up care," said Dr. Karin Sorenmo, chief of oncology at the Matthew J. Ryan Veterinary Hospital. "This means that we can capture all the data that is needed for the study while pet owners are helped financially."

Prior gifts to The Matthew J. Ryan Veterinary Hospital from the Foundation have been a respirator for their ICU department and a mast cell tumor research study.

Dr. Sorenmo treated Breezy, who had mast cell tumors. "Thanks to Dr. Sorenmo, Breezy lived another 2 years, of quality life, after other vets gave her only 6 weeks to live," said Wanda Shefts. "We are glad that this project will help owners of dogs in remission from lymphoma and help advance Dr. Sorenmo's work on the cancer vaccine.

Dr. Sorenmo stated that she was encouraged by the results and she is hoping that this is just the beginning of more trials that can benefit dogs and ultimately help people. Thanks to this study, a number of the participating dogs are now cancer free. The researchers now estimate that they are within two years of testing the vaccine on humans. Without the dogs, they would be more than a decade away.

"We have a tremendous amount of respect for the work they do at the Hospital and we are glad to be able to fund another project for them", said Mark Shefts.

For more information about Penn Vet, please visit www.vet.upenn.edu; for more information about The Onyx and Breezy Foundation, please visit www.onyxandbreezy.org.

The Onyx and Breezy Foundation Background

The Foundation was created in 2004 and named after the trustees Mark & Wanda Shefts' two Labrador Retrievers. The Foundation lends financial support to organizations that benefit the welfare of animals.

The University Of Pennsylvania School Of Veterinary Medicine Background

Penn's School of Veterinary Medicine is one of the world's premier veterinary schools. Founded in 1884, the School was built on the concept of Many Species, One MedicineTM. The birthplace of veterinary specialties, the School serves a distinctly diverse array of animal patients, from pets to horses to farm animals.

Press Contact: Barbara Kauffman
Company Name: The Onyx & Breezy Foundation
Phone: 201-782-7400
Website: www.onyxandbreezy.org

New, Flexible Individual Health Insurance Plans

HumanaOne Introduces New, Flexible Individual Health Insurance Plans in Nine States

Individual insurance plans from HumanaOne meet a wide range of consumer needs.

Louisville, KY  -  March 11 -- Humana (NYSE: HUM) today announced the introduction of a new portfolio of individual health insurance plans under its HumanaOne® brand in nine states -- Alabama, Arkansas, Iowa, Indiana, Mississippi, Nebraska, Oklahoma, South Carolina and Utah. In 2007, Humana introduced the individual health insurance coverage options in 15 other states (listed below), where they have been popular with consumers.

The variety of plans makes it easy for individuals and families to select a plan according to their own personal preferences, lifestyles and budgets. HumanaOne plans are designed specifically for self-employed entrepreneurs, small-business employees, part-time workers, students and early retirees. Humana markets HumanaOne plans through insurance agents and brokers, as well as directly to consumers. Health insurance quote applications for the plans are available online or by phone.

HumanaOne's new personal health insurance plan portfolio includes a broad spectrum of benefits -- with three in-network coinsurance levels and 17 annual deductible choices -- organized into three, distinct packages, for:

•    People who are security-minded and want benefits like those provided by big employers
•    People who want flexibility to fit their financial plan, including HSA-qualified offerings
•    People who want a low-cost plan with a safety net "just in case"

The plans can be further customized with optional benefits such as dental insurance, life insurance, and supplemental accident coverage.

"With the U.S. market for individual health insurance at 18 million and growing, we recognize that individual health insurance plans cannot be 'one size fits all,'" said Jerry Ganoni, president of HumanaOne, Humana Small Business and HumanaDental. "That's why we created three separate families of plans, each tailored for a particular kind of consumer, but at the same time highly customizable. This represents the most significant product expansion for HumanaOne since its inception in 2002."

In 2007, Humana launched the new products in 15 other states -- Arizona, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky, Louisiana, Michigan, Missouri, North Carolina, Ohio, Tennessee, Texas and Wisconsin. Soon, the company plans to introduce the new product portfolio in the remaining two states where HumanaOne currently operates. At present, HumanaOne serves more than 250,000 health plan members in 26 states.

The new plans from HumanaOne are designed to appeal to a variety of consumers -- from those who desire the security, coverage and service commonly found in health plans from large employers, to those wanting a simple safety net in the event of a major health problem.

The new portfolio of HumanaOne plans offers deductibles ranging from $1,000 to $7,500 for single coverage, and from $2,000 to $15,000 for family coverage. Premiums start as low as $30 per month for single coverage and increase according to the plan, its features and level of benefits.

"This new portfolio of products positions HumanaOne to serve a much larger portion of the individual health insurance market, which we believe will continue to grow at a rate of five to eight percent annually over the next five years," said Steve DeRaleau, chief operating officer of HumanaOne. "As more people leave group health plans, retire early, become self-employed or work part-time, they will increasingly look to individual health plans, and HumanaOne will be there to serve them with a plan ideally suited to their distinct needs."

Humana guarantees monthly premium rates on its HumanaOne plans for one full year after purchase, as long as the member remains in the same area and keeps the same benefits. Thanks to Humana's large network of doctors and hospitals, HumanaOne policyholders who move to a different state can simply take their plan with them, and in most cases, those who work or travel away from home can receive in-network benefits by seeing any of the more than 400,000 Humana-contracted doctors, hospitals and other health care providers across the country.

HumanaOne members have 24-hour access to online tools and resources, enabling them to check claims status, medical expenses, compare hospital, doctor and prescription costs and more. HumanaOne accepts applications by phone or via its Website at http://www.humana-one.com/.

About Humana

Humana Inc., headquartered in Louisville, Kentucky, is one of the nation's largest publicly traded health and supplemental benefits companies, with approximately 11.5 million medical members. Humana is a full-service benefits solutions company, offering a wide array of health and supplementary benefit plans for employer groups, government programs and individuals.

Over its 47-year history, Humana has consistently seized opportunities to meet changing customer needs. Today, the company is a leader in consumer engagement, providing guidance that leads to lower costs and a better health plan experience throughout its diversified customer portfolio.

More information regarding Humana is available to investors via the Investor Relations page of the company's web site at Humana.com, including copies of:
•    Annual reports to stockholders
•    Securities and Exchange Commission filings
•    Most recent investor conference presentations
•    Quarterly earnings news releases
•    Replays of most recent earnings release conference calls
•    Calendar of events (includes upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)
•    Corporate Governance Information

Press Contact: Jim Turner
Company Name: HumanaOne
Phone: 502-476-2119
Website: http://www.humana-one.com/

Suboxone Treatment Program Launched

InterventionTreatment.com Launches Suboxone Treatment Program

LOS ANGELES-- June 27, 2008 --Intervention Treatment announced today that it has launched a suboxone treatment program. The program will be used to increase Intervention Treatment's Global mission of providing Intervention and Treatment resources to those affected by alcohol and drug addiction. According to Dr. Jason Schiffman, Chief Medical Officer for Intervention Treatment, "There is a large, poorly met demand for outpatient, office-based treatment of opiate dependence and the addition of the suboxone treatment program to Intervention Treatment's array of alcohol and drug addiction related services will be a great tool for patients and their families."

Intervention Treatment is currently one of the fastest growing online resources for those affected by drug and alcohol addiction. The new Suboxone Treatment program is designed to help those affected by opiate addiction.

About Suboxone:

Suboxone is the first drug approved by the FDA for opiate dependence treatment in office based settings. This means that patients addicted to opiates may now choose to receive opiate-based treatment as an outpatient instead of in a hospital setting. Patients are evaluated and treated during office visits and receive a prescription for suboxone which they may fill at any pharmacy. Suboxone is comprised of two separate medications: buprenorphine and naloxone. Buprenorphine is a partial opiate agonist, meaning its opiate effects are significantly reduced compared to that of full opiate agonists, such as vicodin or heroin. The naloxone in suboxone is not appreciably absorbed from the digestive track when suboxone is taken orally and is in place to prevent the misuse of suboxone by injection drug users. The combination of these two medications leads to suboxone's effectiveness in treating opiate dependence.

About Suboxone Treatment:

Suboxone treatment differs significantly from standard opiate dependence treatment programs. Traditionally, opiate addicts undergoing medical detoxification have been administered either methadone or a combination of drugs, each targeting a symptom of withdrawal. The latter approach usually must take place in an inpatient setting in order to be done safely, while methadone treatment requires a patient to visit a clinic on a daily basis to receive a prescribed dose. Suboxone treatment differs from these treatments in several important ways. Firstly, a prescription for suboxone can be obtained at a specially licensed physician's office and filled at any pharmacy. This means the patient does not need to be admitted to a hospital or make daily visits to a methadone clinic in order to receive their medication. Secondly, because suboxone is a mixture of naloxone and buprenorphine, a partial opiate agonist with a long duration of action, the potential for abuse and overdose are much less than with methadone. Thirdly, because buprenorphine is a partial opiate agonist, suboxone may be easier to taper off of than full opiate agonists like methadone.

About Intervention Treatment

Intervention Treatment, formed in 2007, is an internet resource offering help to those affected by drug and alcohol addiction. Intervention Treatment provides referrals to drug and alcohol rehabs, intervention services, suboxone treatment referrals, and general information regarding addiction and treatment.

Safe Harbor Statement

This press release contains statements that may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of the Company, and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contacts

Intervention Treatment
William Donovan, Co-Founder, 949-267-4113
bj@interventiontreatment.com
www.interventiontreatment.com

Baxter Heparin Information on Additional Heparin Recall

LegalView Expands Baxter Heparin Information Portal to Include Information on an Additional Heparin Recall

LegalView updated its Baxter Heparin information portal to add information on the most recent recall of the blood-thinning drug. Heparin, which is used to control blood during surgical procedures, was recently discovered to have a Heparin-like contaminant that sickened many and caused at least 19 deaths.

Denver, CO  -  March 31, 2008 -- The Baxter Heparin practice area on LegalView's site, the source for everything legal on the Web, was recently expanded to explain details of an additional Heparin recall . Heparin has been linked to hundreds of allergic reactions among patients as well as having been connected with 19 deaths. B. Braun Medical Inc. issued the most recent recall of Heparin, which was supplied from Scientific Protein Laboratories - the same company that supplied Baxter Healthcare Corporation with the contaminated Baxter Heparin. According to the U.S. Food and Drug Administration (FDA) and B. Braun Medical Inc., no one was reportedly sickened off of the Heparin from B. Braun Medical but it did have a "heparin-like contaminant," which was enough for the company to recall the drug.

Heparin is blood-thinner injected into patients who are undergoing surgical procedures such as heart disease or kidney dialysis. It is a drug that has been imported to the United States since the 1930s and is derived from pig intestines. Many surgeons find that Heparin is an extremely important drug because it prevents blood clots from forming during surgery, which can result in death among patients. However, earlier this year, a rash of individuals who had been given Heparin during a surgical procedure had allergic reactions. Individuals who have been affected by the contaminated Heparin should consider contacting a Heparin lawyer to learn about developing a Heparin class action lawsuit for which compensation may be derived from manufacturers if the tainted drug.

The Baxter Heparin that was initially recalled had been tainted with a chemical known as over-sulfated chondroitin sulfate. Through an FDA investigation, it was discovered that a Chinese company that produces the drug was responsible for the tainted Heparin. Although an investigation continues to be ongoing as to whether the chemical was intentionally or accidentally introduced into a batch of the Heparin. According to news reports, using the over-sulfated chondroitin sulfate allows for a reduction in the production of production for Heparin.

For information on additionally recalled prescription drugs or to report an adverse reaction to a prescribed drug, visit LegalView's many unsafe drugs information portals. Here, readers will find information on recently recalled drugs as well as prescription drugs under investigation such as Chantix, Avandia and Trasylol Aprotinin.

Chantix is a smoking cessation drug from Pfizer that was first introduced to the market, with FDA approval, in mid-2006. However, in late-2007 the FDA began an investigation into nearly 400 reports of suicidal tendencies and behaviors among patients. Additionally, nearly 37 suicides have been associated with the Chantix side effects, which include psychotic episodes, depression, suicidal thoughts and erratic behavior.

Avandia is a prescription drug used to treat diabetes 2 among patients; however, the drug has been linked to several serious side effects including an increased risk of heart disease and a higher chance of early onset osteoporosis. Individuals who are taking Avandia are advised to locate an experienced pharmaceutical law firm to receive consultation on an Avandia lawsuit.

Trasylol, also known as its generic version Aprotinin, is similar to Heparin in that it is used during surgical procedures to control blood loss. A study was released in 2006 from the New England Journal of Medicine, which found that the use of Trasylol Aprotinin increased the chances of a patient developing heart disease, kidney disease, stroke and death. Patients who received or may have received Trasylol or it's generic version should use LegalView's information portal to find an Trasylol attorney.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

Press Contact: Katie Kelley
Company Name: LegalView
Phone: 720-771-3246
Website: http://baxter-heparin.legalview.com